Telemedycyna Polska SA
WSE:TMP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
Telemedycyna Polska SA
WSE:TMP
|
PL |
|
E
|
Eagon Industrial Co Ltd
KRX:008250
|
KR |
|
Hardide PLC
LSE:HDD
|
UK |
|
F
|
Flexible Solutions International Inc
AMEX:FSI
|
CA |
|
R
|
Revolution Co Ltd
TSE:8894
|
JP |
|
H
|
HLS Therapeutics Inc
OTC:HLTRF
|
CA |
|
First Western Financial Inc
NASDAQ:MYFW
|
US |
|
WuXi AppTec Co Ltd
SSE:603259
|
CN |
|
Y
|
Yatsen Holding Ltd
NYSE:YSG
|
CN |
|
A
|
Airea PLC
LSE:AIEA
|
UK |
|
Jiangsu Hengli Hydraulic Co Ltd
SSE:601100
|
CN |
|
Lingbao Gold Group Company Ltd
HKEX:3330
|
CN |
|
S
|
Swedish Orphan Biovitrum AB (publ)
OTC:BIOVF
|
SE |
|
T
|
Taekyung Chemical Co Ltd
KRX:006890
|
KR |
|
W
|
Winfarm SA
PAR:ALWF
|
FR |
|
biOasis Technologies Inc
XTSX:BTI
|
CA |
Balance Sheet
Balance Sheet Decomposition
Telemedycyna Polska SA
Telemedycyna Polska SA
Balance Sheet
Telemedycyna Polska SA
| Dec-2020 | Dec-2021 | ||
|---|---|---|---|
| Assets | |||
| Cash & Cash Equivalents |
2
|
2
|
|
| Cash Equivalents |
2
|
2
|
|
| Total Receivables |
1
|
1
|
|
| Accounts Receivables |
1
|
1
|
|
| Other Receivables |
0
|
0
|
|
| Inventory |
0
|
0
|
|
| Other Current Assets |
0
|
0
|
|
| Total Current Assets |
3
|
3
|
|
| PP&E Net |
1
|
1
|
|
| PP&E Gross |
1
|
1
|
|
| Accumulated Depreciation |
1
|
2
|
|
| Intangible Assets |
0
|
0
|
|
| Goodwill |
0
|
0
|
|
| Note Receivable |
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
|
| Other Assets |
1
|
0
|
|
| Total Assets |
5
N/A
|
5
-7%
|
|
| Liabilities | |||
| Accounts Payable |
1
|
0
|
|
| Accrued Liabilities |
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
|
| Other Current Liabilities |
1
|
1
|
|
| Total Current Liabilities |
2
|
1
|
|
| Long-Term Debt |
0
|
0
|
|
| Deferred Income Tax |
0
|
0
|
|
| Other Liabilities |
0
|
0
|
|
| Total Liabilities |
2
N/A
|
1
-30%
|
|
| Equity | |||
| Common Stock |
1
|
1
|
|
| Retained Earnings |
3
|
2
|
|
| Additional Paid In Capital |
5
|
5
|
|
| Total Equity |
3
N/A
|
3
+10%
|
|
| Total Liabilities & Equity |
5
N/A
|
5
-7%
|
|
| Shares Outstanding | |||
| Common Shares Outstanding |
0
|
9
|
|